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1. Introduction 
There is a large number of immunodeficient patients requiring lifelong IgG replacement. 
This review is focused on currently available Intravenous Immunoglobulin (IVIG) 
preparations, manufacturing procedures, dose arrangements, mechanisms of actions, 
benefits of antibody replacement treatment and careful administration of IVIG considering, 
numerous side effects. Subcutaneous IgG (SCIG) treatment has gained ground in recent 
years as an alternative to IVIG. Data show that the efficacy of SCIG in preventing infections 
is proportional to the steady-state levels achieved and similar to that of IVIG.  
Intravenous immunoglobulin (IVIG) is mainly indicated as replacement therapy for patients 
with primary and selected secondary immunodeficiency diseases characterized by absent or 
deficient antibody production. Antibody deficiencies are a heterogeneous group of diseases 
mainly consisting of primary immunodeficiency diseases (PID) [1-4]. Primary antibody 
deficiencies (PAD) can be divided into four main subgroups: X-linked 
agammaglobulinaemia, class-switch recombination defects (hyper-IgM syndromes (HIGM), 
hypogammaglobulinaemia (particularly common variable immunodeficiency (CIVD) and 
selective immunoglobulin deficiencies (selective IgA deficiency). Over the past 20 years, 18 
genetic defects have been defined as leading causes of PAD, but no gene defects were 
identified in patients with hypogammaglobulinaemia and selective immunoglobulin 
deficiencies, because of the variability of the affected stages of B cell differentiation and 
maturation, and the onset time of clinical symptoms like childhood or adulthood with 
increased susceptibility to mainly bacterial infections [5,6].  
Substitution of immunoglobulin G (IgG) is the efficient and standard treatment for many 
years [7-11]. Immunoglobulins pooled from thousands of healthy donors contain a wide 
range of antibody specificities. These immunoglobulin preparations also have anti-
inflammatory and immunomodulatory effects in addition to their use as replacement 
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therapy [12,13]. The benefits in diseases such as childhood thrombocytopenia and Kawasaki 
disease refractory to or intolerant of conventional treatment have been well established 
[14,15]. It has been 30 years since therapeutic contribution of intravenous immunoglobulin 
(IVIG) administration has been proven by scientists, an increasing number of immune-
mediated diseases have been treated with intravenous immunoglobulin rather than 
corticosteroids and cytoxic drugs. IVIG has become the therapy of choice in autoimmune 
diseases, severe asthma, neurological diseases, transplantation, sepsis, septic shock, toxic 
shock syndromes and dermatologic disorders [15,16]. The recommendation of IVIG 
treatment in other diseases than those approved by FDA is based on limited data or some of 
these diseases do not have any alternative treatment regimen to compare with [16]. 
However, IVIG administration in the treatment of many diseases is raising the possibility of 
product shortages and increasing costs. Thus, concerning the shortages of products, cost and 
adverse reactions, definite indications for IVIG treatment are essential [12,13,16,17]. The aim 
of immunoglobulin therapy should be to protect the patients from frequent and severe 
infections finally resulting in organ damage. Advances in human immunology, has led to 
identify responsible genes for PID, thereby particular groups of defects are associated with 
susceptibility to specific types of infection [18]. Improved diagnostic precision is likely to 
increase more specialized management strategies of patients with PID, some of which are 
only supported by expert consultation. However, there are no sufficient number of studies 
in PID, to optimize the quality and uniformity of management of PID.  
2. History and recent development (IVIG)  
Cohn et al produced the first human immunoglobulin IgG product in1946 and it was 
referred as immune serum globulin (ISG)[19]. This first commercial human ISG solution 
tended to form aggregates during storage, therefore it was delivered via the intramuscular 
or subcutaneous route. After diagnosing his first patient with agammaglobulinemia in 1952, 
Bruton began to treat his patients by subcutaneous replacement therapy with ISG [20]. After 
a short time, intramuscular ISG treatment became available for all patients, but the amount 
of Ig used for treatment was limited and not effective enough to reduce recurrent infections 
and the adverse effects were also high due to IgG aggregates [21]. These disadvantages were 
abolished by Cohn fraction II that had been developed in 1960’s by Barandum and his 
colleagues in collaboration with Swiss Red Cross [9,21]. The first IVIG was produced by 
pepsin digestion (enzymatic method: pepsin or trypsin) to reduce anticomplement activity, 
but this process cleaved the immunoglobulin molecule into two parts, resulting in fragments 
of the fc portion and Fab. Several manifacturers produced chemically modified IVIGs 
containing minimal anti-complement activity and no IgG fragments. Reduced bacterial 
opsonic activities and shortened circulating half-lives were demonstated in some antibodies 
of enzyme-digested or chemically modified IVIG preparations. Non-denaturating processes 
such as precipitation with polyethylene glycol (PEG), ion exchange chromatography, 
diafiltration and stabilisation of IgG at low pH, do not modify the IgG molecule and the 
half-life of IgG is generally 22-25 days [21].  
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Intravenous immunoglobulin (IVIG) preparations contain 16% human serum 
immunoglobulin and more than 95% IgG, scanty amount of IgA, IgM and other serum 
proteins. IgA and IgM do not have any therapeutic effects due to their short half-life and 
small amount [22,23]. Prognosis of patients with deficient IgG production has thoroughly 
improved after replacement therapy with IVIG [24]. Since 1980, it has been the most striking 
therapeutic agent due to its unproposed anti-inflammatory and immunomodulatory effects 
and used to treat a wide variety of pathologies including vasculitis, HIV infection, 
autoimmune diseases and immune-mediated neurological diseases [12,14,15, 25-28]. 
Currently, subcutaneous immunoglobulin infusions administered by a special pump has 
become an alternative to IVIG treatment. It has been demonstrated that this product is safe 
and has some clinical advantages over intravenous preparations. It has been recommended 
especially for selected patients with primary immunodeficiencies [29,30]. 
3. IVIG production 
IVIG preparations are derived from plasma of a huge number of human blood donors or 
paid plasmapheresis donors. Since IVIG preparations are blood-derived products having the 
risk of transmission of infectious transfusional diseases, viral safety needs to be considered 
[13,21,23]. The safety of IVIG products depends on donors, validated manufacturing 
processes and various virus clearance steps as listed below: 
a. recruitment of the donor 
b. donation screening 
c. use of validated manufacturing processes 
d. effective viral inactivation/removal procedures 
To produce a single product lot, sufficient number of donor recruitment and screening of 
viral markers (HBs-Ag, HIV-p24 antigen, antibodies to syphilis, HIV-1,HIV-2, HCV, HAV) 
are necessary to prevent the transmission of viruses [21].  
FDA (Center for Biologics Evaluations and Research) and Plasma Protein Therapeutics 
Association recommended the number of donors to be minimum 15.000, but not more than 
60.000. Manifacturing processes implemended in commercial IVIG preparations are the 
classical Cohn fractionations treated with solvent detergent, caprylate, acid or pepsin to 
inactivate pathogens [31-33].  
Immunoglobulin, produced by cold ethanol fractionation method may contain trace 
amounts of contaminants such as prekallikrein activator, prekallikrein, activated 
coagulation factors, complement proteins, IgM, IgA, plasmin and plasminogen. Currently 
many manufacturers began to use purification with anion exchange (DEAE) 
chromatography adjusted to cold ethanol fractionations in order to obtain safe products.  
Treatment at pH4 with trace amounts of pepsin is also validated by some manifacturers. 
Both, alcohol fractionation and acid treatment procedures eliminate other proteins and 
inactivate dangerous live viruses such as HIV, Hepatitis B, HCV. 
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Improved quality standards for plasma products and new blood borne pathogens such as 
SARS forced the scientists to develop and integrate new specific viral inactivation methods. 
RNA virus with lipid envelope, DNA virus with lipid envelope and non-lipid enveloped 
virusus must all removed by viral inactivation procedures. The heat and chemical treatment 
processes are able to remove and/or inactive blood-borne pathogens: 
a. Pasteurisation: Based on heating to 60°C in an aqueous solution for 10 hours in the 
presence of stabilizers. 
b. Solvent/Detergent: The solvent/detergent consists of an organic solvent (ether, 0.3% tri-
n-butylphosphate (TNBT) and 0.2% detergent (Tween 80, sodium cholate or triton-100). 
The process lasts for 6 hours and destroys infectivity of lipid-enveloped viruses. 
c. Nanofiltration: This procedure is effective to remove small non-enveloped (B19V, HAV) 
viruses. 
d. Low pH-incubation: This incubation at elevated temperatures completely removes 
lipid-enveloped viruses like HIV, HBV/HCV). 
Transmission of Prion diseases such as Creutzfeldt–Jakob disease (CJD) or variant CJD by 
administration of blood products is also possible, since the incubation period of the disease 
is too long leading to difficulties in risk determination. Because of this possibility, donors 
who have spent more than 6 months in the United Kingdom from 1986 to the present are not 
allowed to donate blood or plasma in the United States and Europe [21]. Some researchers 
demonstrated that depth filtration step that is common in all IVIG production procedures 
and nanofiltration removed hamster scrapie protein reactivity. The Finish Red Cross Blood 
Transfusion Service (FRC BTS’ Helsinki, Finland) had developed a liquid 5% IVIG product 
(IVIG-L) in which a nanofiltration step was incorporated into the production process [34]. 
Van der Meer JWM et al. evaluated efficacy and safety of that nanofiltered liquid IVIG 
product and showed that IVIG-L was efficacious and pharmacokinetic properties were 
comparable to other IVIG preparations. In addition relatively low level of adverse reactions 
and the absence of seroconversion were observed. Thus, this liquid form product is 
considered to be safe and well tolerable. Over the past years, improved manifacturing 
processes and integrated specific viral inactivation steps have increased the safety and 
quality of IVIG products (Table 1). Commercially available products represent recent 
advancements in IVIG product formulation, but potential transmission of emerging 
pathogens can still not be ruled out completely. 
Currently licensed IVIG preparations are supplied either in lyophilized powder or premixed 
solution, contains 95% IgG at a concentration of 16.5% (165 mg/ml), all the IgG subclasses, 
multiple IgG allotypes (Gm and Km), minimal anti-complement activity, broad spectrum of 
antibodies against viruses and bacteria, and no difference in therapeutic efficacy. Half-life of 
immunoglobulins is approximately 21-25 days. The osmolarity varies between 253 mOsm/L 
for a 5% IgG product to1250 mOsm/L for a 10% product. The final sterile product contains 
varying amounts of sodium, glycine, polyethylene glycol, D-mannitol, D-sorbitol, sucrose, 
glucose or maltose, glycerol as the stabilizer, and thiomersal as the preservative and has a 
pH of 6.8 (Table 2).  
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Virus inactivation/removal procedure Product
Solvent-detergent inactivation Gammagard S/D 
Gammagard liquid 
Flebogamma 5% DIF 
Octagam 
Heat inactivation(10h at 60 C) Vivaglobulin 
Flebogamma 5%  
Flebogamma 5% DIF 
Removal by nanofiltration Gammagard liquid 
Carimune NF 
Privigen 
pH4 incubation (in process) Flebogamma 5% DIF 
Octagam 
Privigen 
Low pH incubation in final container(21 day) Gamunex 
Low pH incubation at elevated temperature in final container Gammagard liquid 
Pepsin treatment Carimune NF 
Caprylic acid virus inactivation Gamunex 
Table 1. Dedicated virus inactivation procedures used in IVIG production [22] 
 
Product Manufactu-
rer 
Dosage 
form 
Sodium 
Content 
mEq/mL
Stabilizing agent 
/PH 
Antimicrobial
processes 
IgA  
µg/mL 
Osmolarity 
mOsm/kg 
Octagam Octapharma 5 %Liquid  0.03 Maltose 
PH 5.1-6 
 Cold ethanol 
fractionation 
Solvent-detergent 
100 310-380 
Gamimune N Bayer 10%Liquid  Trace Glycine 
pH4.25 
 
Dialfiltration, 
Ultrafiltration 
Solvent-detergent 
Trace 274 
Carimune NF 
liquid  
CSL Behring 
AG 
3, 6 ,9,12% 
lyophilized 
<20 sucrose 
1.67 per gram 
protein 
PH 5.3 
 Kistler&Nitchman 
Fractiotion, trace 
Pepsin, pH 4.0 
Nanofiltration 
720 192-1074 
Gammagard 
5% S/D 
Baxter 5% 
lyophilized 
powder 
0.145 2% glucose 
PH 6.8 
Ultrasantrifuge,  
Ion exchange 
chromotography, 
Solvent-detergent 
<2.2. 636 
Gammagard 
10% S/D 
Baxter 10% 
lyophilized 
powder 
0.145 4% glucose 
PH 6.8 
Ultrasantrifuge, Ion 
exchange, 
chromotography, 
Solvent-detergent 
270 1250 
Gammagard 
S/D10% 
(KIOVIG) 
Baxter 10% liquid none glycine 
PH 4.85 
 Cohn-Oncley 
fractionation,  
Ion exchange 
chromotography, 
Nanofiltration, 
Solvent-detergent, 
pH 4 filtration 
37 240-300 
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Product Manufactu-
rer 
Dosage 
form 
Sodium 
Content 
mEq/mL
Stabilizing agent 
/PH 
Antimicrobial
processes 
IgA  
µg/mL 
Osmolarity 
mOsm/kg 
Flebogamma 
DIF 
Grifols 5% , 10%  
Liquid  
<0.032 D-sorbitol 
PH 5.0-6.0 
Cold alcohol 
fractionation, 
PEG, Ion exchange, 
chromotography, 
PH4 treatment, 
Solvent-detergent, 
double sequential 
nanofiltration 
5%: 
< 50 
10%: 
< 100 
240-370 
Venoglobulin 
S 
Alpha 5 % 
10% Liquid  
 Albumin 
(human) 
D-sorbitol 
PEG, Ion exchange 
Chromotography, 
Solvent-detergent, 
24  
Gammar-PIV Centeon, 
L.L.C., 
Kankakee 
lyophilized 0.085 Albumin 
(human) 
Sucrose 
PH 6.8 
 
Cold ethanol 
fractionation, 
heat10 hours 60°C 
25 258 
Iveegam Immuno US lyophilized 
5% 
0.05 Glucose, 
NaCl 
Polyetilene 
glycol/trypsin 
5 >240 
Endobulın Baxter 
Immuno 
France 
lyophilized 3mg Glucose, 
Polyetylene 
glycol(PEG), 
Solvent-detergent   
IgVena Sclavo Liquid   Maltose Solvent-detergent 
pH 4 filtration 
100  
Privigen CSL Behring 
AG 
Liquid Trace 
amount 
None Octanoic acid 
fractionation, 
CH9 filtration, pH 4.0 
incubation, Depth 
filtration, 
Chromotography,  
Nanofiltration , 
≤25 Isotonic 
(320) 
Gamunex- C Talecris 
Biotherape-
utics 
Liquid Trace 
amount 
None Cohn-Oncley 
fractionation, 
caprylate 
precipitation, 
Sepharose 
chromatography, 
Cloth and depth 
filtration 
Final container pH 
4.25 ±0.25incubation 
46 258 
Omr-IgG-am Omrix 
Biopharmac
euticals Ltd 
Liquid  50 mg/mL; 100 
mg/mL maltose 
Cold ethanol 
fractionation, S/D, 
24 h @ pH 4, 
pH 5.5 ± 0.4,  
  
Table 2. Commercial IVIG Products and properties (Data from Immune Deficiency Foundation, 
October 2011 and reference [17, 22])  
All the available IVIG preparations approved by FDA and EMEA should at least have the 
following features:  
• Sterile >4000[5000-10000]donors  
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• >20 days of half life  
• >90 % monomeric IgG  
• Effective IgG subclasses, a profile similar to that of human plasma 
• Complete Fc functions, complement fixation, opsonophagocytosis 
• No pyrogenic and vasoactive agents (kinin or plasmin), protein aggregates  
• Low adverse effects 
• Trace IgA concentration  
• Stabile in solution 
• Low price 
4. Mechanism of action 
Human immunoglobulin is obtained from a large number of donors and exceeding 2.000 
donors is preferred. IVIG contains large spectrum of antibody specificities such as antibodies 
to foreign (non-self) antigens, to self-antigens (natural autoantibodies) and to other antibodies 
(idiotypic antibodies which represents antibody repertoire of each donor [35]. That is the 
reason of the differences between immunoglobulin batches [13,21,35]. The mechanism of 
activity of the substituted IgG is easily understood for immunodeficiency disorders 
considering common pathogen-specific IgG antibodies are replaced by those from the donor 
pool [35]. Thereby, regular intravenous immunoglobulin therapy reduces the incidence of 
infection in these patients compared to their infection rates before IVIG treatment [7-13]. 
Immunomodulatory effect of IVIG therapy depends on several mechanisms. Proposed early 
immunomodulatory effects of IVIG infusion are shown below [35-37]: 
• Modulation of production and release of proinflammatory cytokines and cytokine 
antagonists  
• Functional blockade of Fc receptor on splenic macrophages  
• Neutralization of circulating autoantibodies 
• Neutralization of superantigens  
• Inhibition of complement-mediated damage 
• Changes in solubility and rate of clearance of immune complexes 
On the other hand, IVIG infusion downregulates IVIG-reactive B cell clones in long-term. 
Serum IL-6, IL-8, IL-1Ra and TNFalpha concentrations were increased in patients with 
primary immunodeficiencies following IVIG infusion, without any difference in serum IL-
beta, IFNgamma or IL-2 levels. Understanding these immunomodulatory effects of IVIG is 
essential to define IVIG indications in autoimmune disorders [35-37]. In severe infections 
regarding increased catabolism of IgG, IVIG can be added to antibiotic treatments [16, 17]. 
The concentration of IgG is very important for its pro-inflammatory or anti-inflammatory 
properties. Low-dose IVIG has proinflammatory properties, but high dose IVIG has anti-
inflammatory effects. The proinflammatory properties are dependent on complement 
activation or binding of the Fc fragment of IgG to IgGspecific (FcγR) on effector cells of the 
innate immunity leading to receptor clustering, activation of intracellular signaling pathways 
and finally to cell activation. The anti-inflammatory effect of IgG is still not clear, but IgG is 
known to inhibit the differentiation and maturation of human dendritic cells (DCs), expression 
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of co-stimulatory molecules like CD80 and CD86, both leading to lower self antigen processing 
and presentation [8]. Fc and F(ab′)2 fragments of IgG molecule are both able to suppress of 
DCs. Antibodies with the intrinsic capacity to recognize foreign antigens or common 
pathogen-specific IgG antibodies are replaced by those from the donor pool [35]. 
At a lower dose, administered generally to patients with immunodeficiencies, however, 
IVIG exerts a contrasting effect. DCs of patients with common variable immune deficiency 
(CVID) differentiated in the presence of IVIG and presented with an up-regulated 
expression of CD1a and the co-stimulatory molecules CD80, CD86 and CD40 [38,39]. 
Defective functions of DCs have been associated with predisposition to several pathological 
conditions. CVID patients display high susceptibility to recurrent infections and 
autoimmune diseases that could be due in part to impaired DC functions [38,39].  
Advantages of IVIG administration are the following: 
• Painless administration 
• Absence of proteolysis of the product 
• No sterile abscess  
• Rapid onset of action 
• Easy administration of large doses  
Unfortunately, there are also some disadvantages of IVIG administrations: 
• High cost  
• Requirement for a venous access 
• Long duration of the infusion 
• 5-15% adverse events 
• Severe adverse reactions such as anaphlaxis 
5. IVIG preparations 
In recent years, manufactures aim to develop products that provide a high-yield, safe, well 
tolerated and stable concentrates of polyclonal IgG. Each new intravenous immunoglobulin 
product has to be tested for its biochemical characterization done by standart methods 
focusing on purity, integrity and functionality. Efficacy must be shown by opsonization, 
protein A affinity chromatography and mouse protection tests. Pharmacokinetics of the 
product, the influence of product on vital functions, acute toxicity, anaphylactoid potential, 
thrombogenicity should be evaluated in rats, dogs or a rabbit models. Development of new 
methods for fractionation, combining processes and integrating three dedicated virus 
clearance steps provided fulfilling the clinical requirements for intravenous administration 
of second-generation intravenous immunoglobulins products (Table 2) [21].  
The US Food and Drug Administration (FDA) standardized clinical trials with IVIG in 
patients with primary immunodeficiencies. FDA has proposed to measure the rate of serious 
bacterial infections during regular infusions of investigational IVIG for 12 months to avoid 
seasonal variations. Serious bacterial infection term has to be well defined, thus 
bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, 
and visceral abscess were defined as serious infections [8]. 
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The guidelines for clinical Investigation of human normal Immunoglobulin for Intravenous 
administration of the European Medicines Agency (EMA/CHMP/BPWP/94033/2007 rev.2) 
and FDA recommended that an immunoglobulin product is effective if treated patients 
experience less than 1.0 serious infection per year [21,34]. A new IVIG product must have 
‘intact IgG’ which means pharmacokinetic properties of Immunoglobulin G is similar to 
endogeneous IgG and available other immunoglobulin preparations.  
6. Indications of IVIG treatment 
IVIG, has been licensed by FDA for only 6 clinical indications [8,22,23]: 
1. Treatment of primary immunodeficiencies 
2. Prevention of bacterial infections in patients with hypogammaglobulinemia and 
recurrent bacterial infections caused by B-cell chronic lymphocytic leukemia  
3. Prevention of coronary artery aneurysms in Kawasaki disease  
4. Prevention of infections, pneumonitis, and acute graft-versus-host disease (GVHD) 
after bone marrow transplantation 
5. Reduction of serious and minor bacterial infections, to decrease the frequency of 
hospitalisation in children with HIV 
6. Increase of platelet counts in idiopathic thrombocytopenic purpura to prevent or 
control bleeding 
IVIG therapy has been evaluated in a number of clinical conditions mentioned above and 
categorization of evidence, basis of recommendation and strength of recommendation have 
been established (Table 3 and Table 4) [16].  
 
Categorization of evidence and basis of recommendation 
Ia From meta-analysis of randomized controlled studies 
Ib From at least one randomized controlled study 
IIa From at least one controlled study without randomization 
IIb From at least one one other type of quasiexperimental study 
III From nonexperimental descriptive studies such as comparative, correlation or case 
control studies 
IV From expert committee reports or opinions or clinical experience of respected 
authorities or both  
Strenght of recommendation 
A Based on category I evidence 
B Based on category II evidence or extrapolated from category I evidence 
C Based on category III evidence or extrapolated from category I or II evidence 
D Based on category IV evidence or extrapolated from category I, II or III evidence 
Table 3. Categorization of evidence and basis of recommendation and strength of recommendation [17] 
Benefits  Diseases Evidence Strenght of 
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category recommendation 
Definitely 
beneficial 
Primary immune defects with absent B cells  
Primary immune defects with 
hypogammaglobulinemia and impaired 
specific antibody production 
IIb 
 
IIb 
B 
 
B 
Probably 
beneficial 
Chronic lymhpocytic leukemia with reduced 
IgG and history of infection 
Prevention of bacterial infection in HIV 
infected children 
Primary immune defects with 
normogammaglobulinemia and impaired 
specific antibody production 
Ib 
 
Ib 
III 
A 
 
A 
C 
Might 
provide 
benefit 
Prevention of neonatal sepsis Ia A 
Unlikely to 
be beneficial 
Isolated IgA deficiency 
Isolated IgG4 deficiency 
IV 
IV 
D 
D 
Table 4. Recommendation of IVIG in primary and secondary immunodeficiencies [17] 
7. Treatment of primary immunodeficiencies  
Primary antibody deficiencies [25], account for approximately 65-50% of primary 
immunodeficiencies (PID) [3,40]. Due to defects in critical stages of B cell development, B 
cells areabsent/reduced and B cell functions are impaired in patients with PAD [41]. B cell 
defects are a heterogeneous group of disorders consisting of patients presenting a wide 
variety of clinical conditions ranging from asymptomatic to severe and recurrent infections. 
Patients with selective IgA and IgG subclass deficiencies are often asymptomatic, while 
children with agammaglobulinemia present encapsulated bacterial infections initiating at 6 
months of age. Reduced immunoglobulin concentrations and lack of antibody response 
against protein antigens (diphtheria, tetanus toxoids) or polysaccharide antigens 
(pneumococcal polysaccharide) are well defined in patients with agammaglobulinemia or 
hypogammaglobulinemia [40-42]. Although these patients have frequent or recurrent 
bacterial infections, they could not mount IgG antibody responses against antigens and this 
condition is a clear indication for immunoglobulin replacement therapy (Table 5) [21, 42]. 
Therefore, the aim of replacement therapy is to avoid acute infections, respiratory 
complications such as bronchiectasis, gastrointestinal complications, to improve quality of 
life and to increase life expectancy of patients [17, 22]. The delay in diagnosis of primary 
immunodeficiencies remains a significant problem, as a consequence of delay recurrent 
pneumonias results in structural lung damage such as bronchiectasis, pulmonary 
hypertension and finally cor pulmonale [10].  
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1. Antibody deficiencies
X -linked Agammaglobulinemia(XLA) 
Common variable immunodeficiency(CVID) 
Hyper IgM syndrome 
Transient hypogammaglobulinemia of infancy(selected cases) 
IgG subclass deficiency± Selected IgA deficiency (selected cases) 
Impaired specific sntibody production with normal plasma immunoglobulin evel 
2. Combined immunodeficiencies
All type of severe combined immunodeficiencies(SCID) 
3. Other well-defined immunodeficiency syndromes
Wiskott –Aldrich syndrome 
DNA repair defects; Ataxia-telangiectasia, Nijmegen breakage syndrome 
Di George Anomaly 
Primary CD4 deficiency 
ICF syndrome 
4. Diseases of immune dysregulation
X-linked lymphoproliferative syndrome (XLP) 
Table 5. Primary Immunodeficiencies benefit IVIG treatment 
Evaluation of IVIG use in patients lacking immunoglobulin has demonstrated reduction of 
acute and chronic bacterial infections frequency, pneumonia, days of antibiotic usage, days 
of fever and hospital admission [16]. Retrospective studies in patients with XLA revealed 
that severity and number of infections are decreased depending on IVIG dose. Serious 
bacterial illnesses and enteroviral meningoancephalitis were prevented when maintained 
IgG levels were above 800mg/dL [16,21,42,43]. 
Barıs S et al. evaluated the efficacy of IVIG treatment (500 mg/kg every 3 weeks) in 29 
children diagnosed with CVID. During therapy, median serum IgG levels increased from 
410 to 900 mg/dL. The mean number of respiratory infections per patient per year decreased 
significantly from 10.2 to 2.5. The annual number and length of hospital stays decreased 
significantly from 1.36 to 0.21 and 16.35 to 6.33 days per patient, respectively. The mean 
annual number of antibiotics used decreased significantly from 8.27 to 2.50 per patient. 
Twelve patients had developed bronchiectasis before initiation of IVIG [44].  
Intravenous immunoglobulin therapy has to be started without any delay in patients with 
CVID predisposed to chronic lung diseases. Appropriate replacement therapy in these 
patients, reduced the incidence of pneumonia and prevent progression of lung involvement 
[17, 42-47]. 
A 5-year multicenter prospective study on 201 patients with CVID and 101 patients with 
XLA was conducted to identify the effects of long-term immunoglobulin treatment and the 
IgG trough level to be maintained over time required to minimise infection risk. Overall, 
21% of the patients with CVID and 24% of patients with XLA remained infection free during 
the study. Pneumonia episodes had been reduced. Patients with pneumonia did not have 
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significant lower IgG trough levels than patients without pneumonia, with the exception of 
patients whose IgG trough levels were persistently <400 mg/dL. In addition, in XLA co-
morbidity risk factor identified for pneumonia was the presence of bronchiectasis [10,23].  
Studies have shown that 10 years survival of CVID patients receiving IVIG treatment was 
78%; while expected survival in the general population at ten year was 97% [28].  
Patients with severe combined immunodeficiency(SCID) syndromes are also 
agammaglobulinemic and have significant inability to produce antibody against antigens. 
Hematopoietic stem cell transplantation is choise of therapy for these patients, but 
functional B-cell reconstitution often fail following marrow engraftment and these patients 
could not produce antibodies. Regular replacement therapy with IVIG is indicated for these 
patients.  
Hyper IgM syndromes are usually defined with reduced levels of IgG and IgA, but high or 
normal IgM. These patients have normal B cell counts, but defective class switching do not 
allow to generate specific antibodies, thus these children experience frequent infections like 
agammaglobulinemic individuals. Adequate replacement of IVIG has been shown to reduce 
the incidence of pneumonia from 7.6% to 1.4% per year and patients did not have meningitis 
[10, 25, 48]. 
Selective antibody deficiencies or normogammaglobulinemia with impaired specific 
antibody production are group of disorders characterized by impaired production of 
specific antibody with normal serum IgG levels. Evidence of recurrent infection and absent 
or reduced specific antibody production against polysaccharide antigens after vaccination, 
are requirements for IVIG therapy. Therapy can be stopped after clinical improvement and 
the immune response of patient should be re-evaluated at least 5 months later. Usually 
antibody response to antigens, improve in growing children, but in conditions of 
unresponsiveness to antigens, restart to IVIG treatment is appropriate due to recurrence of 
infections. 
Immunoglobulin treatment is not commonly recommended to patients with selective IgA 
deficiency unless poor specific antibody or IgG2 subclass deficiency exists [21].  
Replacement therapy is also recommended in patients with combined immune deficiencies, 
other well-defined immunodeficiency syndromes and X-linked lymphoproliferative 
syndrome (XLP)(Table 5). 
8. Choosing a commercial brand for IVIG therapy  
There are several factors required for selection of an IVIG brand: 
1. To obtain enough information about the IVIG product: lyophilized powder or premixed 
solution, amount of sodium, IgG and IgA, stabilizing sugar, preservative, viral 
inactivation methods, concentration, osmolarity  
2. Safety and tolerability  
3. Price 
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Regarding lyophilized or liquid forms, sugar content, amount of IgA (varies between <0.4 
μg/mL and 720 μg/mL), used antimicrobial processes and stabilizing agent, an appropriate 
commercial immunoglobulin preparation should be selected for treatment of 
immunodeficient patients(Table 1). The patients with diabetes may have high blood glucose 
levels due to maltose-containing products therefore they have to adjust doses of insulin [5, 8, 
21, 23, 49].  
Patients with selective IgA deficiency carry the risk of anaphylaxis due to production of 
anti-IgA antibodies. Selective IgA deficient patients having high anti-IgA (>1/1000) titers 
should not be treated with IVIG or a IgA-free immunoglobulin product should be chosen for 
the treatment [8, 21, 50, 51]. Since IVIG administration is a life-saving therapy, the treatment 
should be supported by scientific clinical evidence regardless the economic impact of 
therapy [52]. Therefore considering scarcity of resource for IVIG, its judicious use must be 
promoted for the diseases FDA approved. 
9. Dose 
The common recommended dose of IVIG treatment for antibody replacement is between 0.3 
and 0.6 g/kg, administered every 2 to 4 weeks via the intravenous route. The first dose of 
IVIG infusion usually results more frequently in adverse reactions compared to the 
following second or third doses. Thus, the first IVIG infusion to a patient with antibody 
deficiency must be given slowly as a 5% solution, starting with a rate of 0.5 to 1.0 mg/kg per 
minute. Patient should be monitored closely for any adverse reactions during infusion. If the 
patient tolerates well, the infusion rate may be increased to 1.5 to 2.5 mg/kg per minute after 
15 to 30 minutes. The maximal infusion rate is 4 mg/kg per minute. Infusion of an IVIG 
product should last 2 to 4 hours. For subsequent infusions IVIG concentrations of 10% and 
12% can be used, with rates 4 mg/kg per minute. The aim of IVIG therapy in patients with 
PID is to maintain serum IgG levels between 350 mg/dl and 500 mg/dl 
[7,10,16,17,25,42,43,45,48,51].  
Since, there is large variation in individual IgG elimination rates, periodic measurement of 
serum IgG concentration is critical to monitor the adequacy of replacement during therapy. 
10. Adverse effects of IVIG 
There are two main risks of immunoglobulin treatment: Infusion related adverse effects and 
transmission of blood–borne viruses [5,7,22,23]. Incidence of adverse reactions, have been 
found 44% in more than 1.000 patients with PID, in a study done by Immune Deficiency 
Foundation (IDF) [16]. This rate was surprisingly higher than those observed in licensing 
studies (Table 6). The IDF survey showed that 34% of patients experienced adverse reactions 
during the first administration of IVIG and who has had a recent bacterial infection. 
Reactions may develop 1 to 15% in the first 30 minutes of IVIG infusions. After second or 
third doses of the same IVIG product additionial infusion dependent reactions become less 
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likely. Most IVIG reactions are mild, however anaphylaxis may occur occasionally. Adverse 
reactions are characterized by chills, headache, low grade fever, back or abdominal pain, 
nausea, vomiting, myalgias, rhinitis, asthma, flushing on face, vertigo, anxiety, conjunctival 
congestion, occasional rash and drop of arterial pressure. Varying rates of adverse events 
have been reported (Table 6) [53-56]. Thus, close monitoring of a patient during infusion is 
essential to identify and manage reactions [8,24,53]. Recently, manufacturing processes of 
immunoglobulins have been improved and new IVIG products have been developed. 
Several trials with these products demonstrated that the infusion related adverse reactions 
were reduced [24,53]. IVIG infusions have to be done at hospital or home by professionally 
educated staff if possible. Local anesthetic cream (EMLA Cream) could be applied on skin 
prior infusion to reduce pain in small children. Administration IVIG via indewelling venous 
catheter is not encouraged because of additional adverse events such as thrombotic and 
infectious complications.  
 
Product Study
Duration
Months 
Patients 
Treated 
Dose Acute
Serious 
Bacterial 
Infect/subj/y
Other 
Bacterial 
Infect/subj/y
Related, 
Temporally 
Associated 
AEs (%of 
Infusions 
Drug-
Related 
SAEs 
CarimuneNF 
Liquid (12%) 
6  42 200-800 
mg/Kg/21–
28 d 
0 3.65 21.7% a 0 
Flebogamma 
5%  
12 51 300–600 
mg/Kg/21–
28 d  
0 061. NR 8.2% c 2 
Flebogamma 
5% DIF  
12  46 300–600 
mg/Kg/21–
28 d 
0.021  1. 96  11.8% c 0 
Gammagard 
liquid 10% 
12 61 300–600 
mg/Kg/21–
28 d 
0 0.07 31.2% c 2 (1 patient) 
Gamunex 
10%  
9 73 100–600 
mg/Kg/21–
28 d  
0.07 0.18  5.7% a 0 
Octagam 5%  12 46 300–600 
mg/Kg/21–
28d.  
0.1 0 5.5% b 0 
Privigen 10%  12 80 200–888 
mg/Kg/21–
28 d  
0.08 3.55 18.5% b 5 (1 subject) 
Vivaglobin 
16%  
15 51 34–352 
mg/Kg/ 
wk  
0.04 4.4 Local, 49%;  
Systemic 
5.4% 
0 
AE:Adverse event, infect/subj/y: infections per subject per year, NF:nanofiltration, SAE:serios adverse event a) 0-48 h 
postinfusion, b) 0-430 min postinfusion, c) 0-72 h postinfusion 
Table 6. Clinical trials in patients with primary immunodeficiency disorders [22] 
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11. Late-onset side effects of IVIG 
A variety of side effects due to IVIG therapy have been reported in different tissues [7-11,21-
25,27,28,57]: 
Central nervous system: rarely aseptic menengitis 
Hematologic: hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated 
intravascular coagulation and changes in blood rheology 
Cardiovascular system: rarely heart attack, most commonly, drop in arterial blood pressure 
Urogenital system: During the period between June 1985 and November 1998, 88 cases of 
kidney injuries had been reported to FDA. Acute renal failure occured with IVIG preparations 
stabilized with sucrose, where as those stabilized with D-sorbitol did not cause such an effect. 
Patients whose urinary output decreases, who suddenly gain weight with edeme on feet and 
ankles and those who experience dyspnea should be monitored very closely.  
Liver Disease: The risk of Hepatitis C, Hepatitis B, HIV infection, prion disease disappeared 
after the initiation of viral inactivation (solvent-detergent or pasteurization) methods and PCR 
studies which took place after CDC’s confirmation of 88 infections among 137 suspected 
hepatitis C cases (occuring after IVIG) in 1994. Therefore they are reliable preparations.  
Skin: severe cutaneus vasculitis, dermatitis (egzema) and hair loss  
Other: Life threatening parvovirus B19 has occured due to IVIG, hyperproteinemia, 
increased serum viscosity, pseudo-hyponatremia during infusions, transient serum sickness. 
12. How to manage adverse reactions? 
An expert monitoring is necessary for prompt diagnosis and treatment of adverse reactions. 
Most side effects resolve by themselves and are usually due to the speed of infusion. Infusion 
should temporarily be stopped 15 to 30 minutes if the symptoms appear or should be 
continued with slower rate once the symptoms disappear. Since the side effects are usually 
non-IgE dependent, the use of antihistamines is controversial, but diphenhydramine, 
acetaminophen or ibuprofen may be helpful. More severe reactions can be treated with 50 to 
100 mg of hydrocortisone in adults and intravenous hydration is helpful. 
Those who are reactive to IVIG should receive premedication. Thirty minutes prior to IVIG 
administration, oral nonsteroid anti-inflamatory agent (acetaminophen 15 mg/kg), 
antihistaminic agent (Benadryl 1mg/kg) or one hour prior to infusion intravenous 
hydrocortisone (6 mg/kg) should be administered [8,24]. 
13. Subcutaneos immunoglobulin 
As an alternative to intravenous immunoglobulin treatment, immunoglobulins can be 
administered subcutaneously to patients with primary immunodeficiencies, Subcutaneous 
infusion of IgG was introduced more than 20 years ago but has gained ground in recent 
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years [29,30,58-64]. Three ready-to-use liquid preparations of human IgG specifically 
formulated for subcutaneous infusions have been lisenced in US (Table 7). It can be stored at 
a temperature up to 25°C. 
 
Product Manufacturer Dosage 
form 
Sodium 
Content 
Stabilizin
g agent 
/PH 
Antimicrobial
processes 
IgA  
µg/mL 
Osmolarity 
mOsm/kg 
Gammagard 
S/D10% 
Baxter 
Corporation 
10% liquid 
<40 kg:20 
mL/hr/site 
>40 kg:30 
mL/hr/site 
none glycine 
PH 4.85 
Cohn-Oncley 
fractionation,  
Ion exchange 
chromotography, 35 
nmNanofiltration, 
Solvent-detergen, pH 4, 
elevated temperature 
incubation  
  
37 
240-300 
 
Hizentra 
BayerC CSL 
Behring 
CSL Behring 
20% Liquid   
Trace 
<10mmol/L 
 
pH4.6-5.2 
Cold alcohol fractionation,
Octonic acid fractionation
Anion exchange 
chromatography,Depth 
filtration 
 Nanofiltration, 
pH4.0incubation TSE 
reduction steps include;  
Octonic acid fractionation,
Depth filtration and virus 
filtration 
 
<50 
 
380 
Vivaglobulin  CSL Behring  16% 
liquid 
3mg/mL none Cold alcohol fractionation,
Ethanol-fatty alcohol/pH 
precipitation, 
pasteurization,  
Diafiltered and 
ultrafiltered 
<1700 
μg/mL 
445 
Table 7. Commercial subcutaneous IG Products(Immune deficiency Foundation, October 2011) 
The infusion can be applied through fine butterfly needles under the skin into the abdomen 
or thighs. Infusion pumps are used to administer the infusions and usually take 45 to 90 
minutes. The amount of fluid given weekly to babies and children is 10 mls per site and 30 
mls per site for older children. Subcutaneous infusion of 10-20% immunoglobulin, with the 
rate of 0.05-0.20 ml/kg/hour is advised. The recommended maintenance dose is 100 
mg/kg/week. Immunoglobulin trough levels should be >5 g/L for patients with 
agammaglobulinaemia and 3 g/L greater than the initial IgG level for patients with CVID; 
however, the clinical response should be consider in choosing the dose and trough level 
[24]. Parents and patients can be educated on how to infuse the preparation at home. These 
infusions are better tolerated compared to IVIG and time sparing (home administration). 
Subcutaneous infusions are recommended to patients who are small children or reactive to 
IVIG or have poor veins. 
Bioavailability and pharmacokinetics properties of subcutaneous IgG (SCIG) differs from 
intravenous IgG (IVIG). There are still debates about how the dose should be adjusted when 
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switching from IVIG to SCIG. Berger M et al reported that the doses that will yield desired 
serum levels for IVIG and SCIG may be estimated with the help of pharmacokinetic studies 
[8]. Area under the curve (AUC) of serum IgG versus time and trough level ratios (TLRs) on 
SCIG/IVIG were evaluated as guides for adjusting the dose. The mean dose adjustments 
required for non-inferior AUCs with 2 different SCIG preparations were 137% (± 12%) and 
153% (± 16%). However, there were wide variations between adjustments required by 
different subjects, and in the resulting TLRs. Recent studies allow estimation of the ratio of 
IgG levels with different dose adjustments, and of the steady state serum levels with 
different SCIG doses [8]. When switching a patient from IVIG to SCIG, practising 
immunologist can tailor the dosage based on measured serum IgG levels and the clinical 
response Skoda-Smith S et al recommended a sample calculation process for converting 
from IVIG to subcutaneous IG, thus weekly dose for subcutaneous Ig should calculate as 
1.37 X IVIg dose [65].  
Safety and therapeutic efficacy of subcutaneous immunoglobulin products has been 
demonstrated in children and pregnant women. Therapeutic efficacy of intravenous or 
subcutaneous immunoglobulin treatment in reducing infections was equal [5,28,57,65,66]. 
In an international study performed by Chapel et al. the efficacy of immunoglobulin 
replacement therapy given via intravenously or subcutaneously in patients with PAD was 
compared [60]. Forty patients received subcutaneous or intravenous immunoglobulin for 
the first year and switched to the alternative treatment in the second year, and the study 
showed that there was no difference in efficacy and adverse reactions between both 
routes. In another study, Fasth A et al. used a 16%, ready-to-use human normal 
immunoglobulin solution subcutaneously in children with PID previously receiving 
regular IVIG treatment, and the study showed that mild injection reactions were the 
adverse effects of the treatment, and the rate of bacterial infections was not different 
between both IVIG treatments. In the at home treatment there were fewer missed school 
days, low healthcare expenses [62].  
The cost effectiveness of the use of subcutaneous IG compared to IVIG therapy had been 
investigated in several studies [67,68]. The mean cost of both immunoglobulins was 
evaluated in the study performed by Beaute J et al. and they showed that monthly doses 
were equal for both routes of administration. In addition SCIG and IVIG (hospital-based) 
costs were also similar, but the costs may differ from one country to another [52]. Although 
this theoretical model showed little difference between the costs, SCIG seems to be 
expensive compared to IVIG due to the doses of immunoglobulin, but further studies are 
needed. Overall costs may be higher in CVID, because these patients need higher doses of 
immunoglobulin [21,52]. 
The SCIG home therapy was reported to give better health and improved school/social 
functioning for the children, reduced emotional distress and limitations on personal time for 
the parents and fewer limitations on family activities [58-64]. Pharmacokinetic studies reveal 
a more physiologic profile, in peak and trough levels of serum IgG [62,66]. Local tissue 
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reactions are more frequent but the systemic side effect profile is low. Local tissue reactions 
are often mild and tend to improve over time. Adults switching therapy reported improved 
vitality, mental health, and social functioning. Treatment satisfaction (TS) scores and health-
related quality of life (HRQOL) was improved in adults and children with 
immunodeficiency [69].  
According to ESID registry (http://www.esid.org), 4462 of 10,039 patients with PID receive 
IgG replacement (74% intravenous, 26% subcutaneous, <0.5% intramuscular). There is a 
wide variety of frequency of subcutaneous IgG replacement therapy in European countries. 
Sweden was the first country to deliver IgG via the SC route, therefore more than 80% of all 
patients with antibody deficiencies receive SCIg [3]. 
14. Conclusion 
Replacement therapy with immunoglobulin either via intravenous or via subcutaneous is in 
patients with immunodeficiencies are associated with reduced infection frequency and 
organ damage and increased life expectancy. IVIG has been widely used in US and Europe 
for many years. Monthly IVIG treatment offered steady-state IgG level throughout the 
dosing cycle, dedicated viral inactivation steps improved safety concerns, pooled analyses 
confirmed the efficacy and safety, benefits of therapy and adverse events has been welll 
established. 
Recent advances in the basic science of immunoglobulins and meta-analyses of patient data 
have provided new approaches in using polyclonal IgG to treat patients with primary 
immunodeficiencies. The old fashion subcutaneuos IG infusion reintroduced to treat 
patients with immunodeficiencies. The subcutaneous-IG therapy was reported to be 
effective, safe and well tolerated in children and adults. In addition, the SCIG home therapy 
high treatment satisfaction (TS) scores and health-related quality of life (HRQOL) was 
advantages of SCIG. Subcutaneous infusions are recommended to patients who are small 
children or reactive to IVIG or have problem with vascular access. Practicing immunologists 
can use new concepts in tailoring their approach to treat patients with primary 
immunodeficiencies. 
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